Article Text

Download PDFPDF
HEART FAILURE
Treatment strategies for heart failure: β blockers and antiarrhythmics
  1. Aldo Pietro Maggioni
  1. Director of the Research Center of the Italian Association of Hospital Cardiologists (ANMCO), Firenze, Italy
  1. Aldo P Maggioni, MD, ANMCO Research Center, Via La Marmora 34, 50121 Firenze, Italymaggioni{at}anmco.it

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The role of β blockers and antiarrhythmic drugs in the management of patients with heart failure is reviewed.

β Blockers

Although several investigators since the 1970s proposed β adrenergic blocking agents as a possible treatment for patients with heart failure,1 the simple observation that they can reduce myocardial contractility confined them to being absolutely contraindicated for the treatment of this condition. However, the medical approach to heart failure has changed dramatically over the past 10 years, progressing from a haemodynamic to a neurohormonal pathophysiological paradigm.2 Since activation of the sympathetic system is recognised as one of the cardinal pathophysiologic abnormalities in patients with chronic heart failure,3 the effects of β adrenergic receptor blockers have been specifically tested in randomised clinical trials. Consequently, over a relatively brief period of time, a treatment that was once contraindicated is now an established, evidence based recommended treatment for heart failure.

Rationale for use

The concentrations of circulating catecholamines are increased in patients with chronic heart failure.3 The adrenergic activation observed in these patients can be useful initially to maintain an acceptable cardiac performance by increasing contractility and heart rate, but ultimately the increase in the adrenergic drive can damage the failing human heart.4 In the human cardiac myocyte, there are three adrenergic receptors—β1, β2, and α1—whose activation can lead to cardiac myocyte growth (β1, β2, α1), positive inotropic response (β1, β2), positive chronotropic response (β1, β2), myocyte toxicity (β1, β2), and myocyte apoptosis (β1).5 Therefore, the continuously increased activation of the adrenergic system leads to several adverse biological signals to the cardiac myocytes through the adrenergic receptors. The rationale for the use of β adrenergic blocking agents in patients with heart failure is based mainly upon these observations.

Effects on physiologic end points

Left ventricular function and remodelling processes

All available trials testing β blockers versus placebo showed that, apart from short term negative …

View Full Text